Latest Biotechnology News

Page 27 of 80
Skin Elements Limited reports successful completion of key product evaluations and secures $2.5 million placement to fuel growth and commercialisation in 2026.
Ada Torres
Ada Torres
31 Oct 2025
Tryptamine Therapeutics has initiated the world’s first clinical trial of its IV-infused psilocin drug, TRP-8803, targeting Binge Eating Disorder, alongside a pioneering EEG biomarker collaboration and new funding.
Ada Torres
Ada Torres
31 Oct 2025
Inhalerx Limited tapped $247,000 from a $38.5 million funding facility to support its clinical trials, while reporting a $310,000 cash burn in operating activities for the September quarter.
Ada Torres
Ada Torres
31 Oct 2025
Chimeric Therapeutics has progressed its CHM CDH17 and CHM CORE-NK clinical trials with promising safety and efficacy signals, while securing a key manufacturing partnership and appointing a renowned haematologist to its board. However, the company faces a pressing cash runway challenge.
Ada Torres
Ada Torres
31 Oct 2025
Hexima Limited reports a steady cash balance of AUD 1.44 million with a modest quarterly operating cash burn, while exploring strategic options including a potential capital return to shareholders.
Ada Torres
Ada Torres
31 Oct 2025
Cleo Diagnostics has secured positive FDA feedback and nearly 1,600 biobank samples, accelerating its ovarian cancer blood test development ahead of a planned 2026 U.S. market entry.
Ada Torres
Ada Torres
31 Oct 2025
Cynata Therapeutics is on track to deliver key clinical trial results in mid-2026 while maintaining a solid cash runway supported by an imminent R&D tax rebate and equity facility.
Ada Torres
Ada Torres
31 Oct 2025
Avecho Biotechnology advances its pivotal Phase III CBD insomnia trial with 160 patients dosed and secures $2.5 million to accelerate manufacturing and regulatory efforts ahead of a 2026 interim analysis.
Ada Torres
Ada Torres
31 Oct 2025
Nexsen Limited has successfully completed an $8 million IPO and ASX listing, while advancing its kidney diagnostic tests and initiating clinical trials for its GBS Rapid Sensor targeting expedited FDA approval.
Ada Torres
Ada Torres
31 Oct 2025
Imugene Limited reports an 81% overall response rate in its azer-cel CAR T-cell therapy trial for difficult lymphomas, alongside a $25 million capital raise that extends its cash runway to mid-2027.
Ada Torres
Ada Torres
31 Oct 2025
Clarity Pharmaceuticals has bolstered its financial position with a $203 million institutional placement and reported positive Phase II trial results for its lead prostate cancer diagnostic, Cu-SAR-bisPSMA. The company also expanded its pipeline with promising preclinical data on a pan-cancer agent and secured a key copper-67 supply agreement to support future commercialisation.
Ada Torres
Ada Torres
31 Oct 2025
Memphasys has sharpened its commercial focus on the Felix™ System, securing a major distribution expansion in the MENA region and cutting operational costs by 40%, setting the stage for a global market push.
Ada Torres
Ada Torres
31 Oct 2025